Illumina Introduces the Infinium® HD HumanOmni1-Quad BeadChip
Product News May 21, 2009
Illumina, Inc. has announced a new product for DNA Analysis: the HumanOmni1-Quad BeadChip. With over four million data points on a single BeadChip, this array includes up-to-date content for all major classes of genetic variation for the study of human disease.
The BeadChip utilizes tagSNPs from all three phases of the International HapMap Project and offers coverage of known regions of copy number variation (CNV) and SNPs of known disease association.
In addition, the HumanOmni1-Quad BeadChip is the first commercially-available product to offer content derived from the 1,000 Genomes Project. The format of the HumanOmni1-Quad BeadChip supports simultaneous genotyping of four samples which increases throughput and decreases the per sample price. First customer shipments of HumanOmni1-Quad BeadChips are expected in June 2009.
“For researchers performing whole-genome SNP and CNV studies, the HumanOmni1-Quad BeadChip provides the fastest and most cost-efficient tool for finding meaningful disease-associations,” said Jay Flatley, CEO and president of Illumina. “This array enables an unparalleled, comprehensive view of the genome and demonstrates Illumina’s commitment to providing the most relevant and valuable content to our customers so they can make new discoveries faster.”
The HumanOmni1-Quad BeadChip targets more than 11,000 regions of both common and rare copy number variation developed in collaboration with The Centre for Applied Genomics at the Hospital for Sick Children in Toronto, the Wellcome Trust Sanger Institute in the United Kingdom and Harvard Medical School / Brigham and Women's Hospital.
BeadChip content also includes over 30,000 non-synonymous SNPs, indels and additional functional variants not found on other arrays. The HumanOmni1-Quad BeadChip delivers carefully selected markers that capture the highest amount of genomic variation and the best power for genome-wide association studies (GWAS) and CNV discovery and screening.